Aura Biosciences develops bel sar, an experimental cancer drug for eye and bladder tumors that is still in clinical trials. It last closed at $6.87 on Nov 20, down 1.58% on the day. The next earnings report for AURA is expected around Mon, Mar 29, 2027. For the quarter ended Sep 2026, AURA reported EPS of -$0.29. Over its last 8 reports the stock moved an average of 5.1% the session after earnings. Over the last 12 months AURA insiders bought $0 of stock on the open market and sold $39.9M, according to SEC Form 4 filings.
AI Auto Pilots
Is AURA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AURA.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on AURAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
AURA · as of the Nov 20 close · updated each morning
Turning up
The stock is 1% above its 20 day and 5% above its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is improving (RSI 51). The nearest support is the 200 day average at $6.82, and the nearest resistance the 100 day average at $6.94.
Short trendBullish
Long trendNeutral
MomentumImproving
StretchNormal
VolatilityHigh, 5.6%/day
Key levels
$9.5452 week high+38.9%
$7.31Swing high (Jul 27)+6.4%
$7.06Pivot R1+2.8%
$6.94100 day average+1.0%
$6.87Swing low (Nov 13)+0.0%
$6.87Last close
$6.82200 day average−0.7%
$6.7820 day average−1.3%
$6.78Pivot−1.3%
$6.59Pivot S1−4.1%
$6.5350 day average−4.9%
$4.7352 week low−31.1%
Indicators
RSI (14)
51.20
Middle of its range
Neutral
MACD
0.17
Below its signal line
Bearish
Stochastic
52.6
Middle of its range
Neutral
ADX (14)
18.7
No clear trend
Williams %R
-56.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
4.3
Oversold below −100, overbought above 100
Neutral
Rate of change
+4.7%
Change over 10 sessions
Bullish
ATR (14)
$0.39
Typical daily range, 5.6% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Above
Moving sideways
Short trendNeutral
Long trendBearish
MomentumFading
StretchNormal
VolatilityNormal, 11.5%/day
Key levels
$9.5452 week high+38.9%
$7.31Swing high (Jul 27)+6.4%
$7.06Pivot R1+2.8%
$6.94100 day average+1.0%
$6.87Swing low (Nov 13)+0.0%
$6.87Last close
$6.82200 day average−0.7%
$6.7820 day average−1.3%
$6.78Pivot−1.3%
$6.59Pivot S1−4.1%
$6.5350 day average−4.9%
$4.7352 week low−31.1%
Indicators
RSI (14)
51.31
Middle of its range
Neutral
MACD
-0.07
Below its signal line
Bearish
Stochastic
38.9
Middle of its range
Neutral
ADX (14)
21.7
Weak trend
Williams %R
-60.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
-2.4
Oversold below −100, overbought above 100
Neutral
Rate of change
−1.8%
Change over 10 sessions
Bearish
ATR (14)
$0.79
Typical daily range, 11.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Below
What happened before, for AURA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how AURA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow AURA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for AURAHow many large options trades hit AURA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in AURA in the last 90 days.
From SEC Form 4 filings by AURA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AURA is in one of them and how their past AURA trades turned out.
Aura Biosciences is a biotechnology company developing drugs to treat solid tumors while aiming to preserve organ function. Its lead candidate, bel sar, is in later stage clinical trials for early choroidal melanoma, a rare eye cancer, and is also being tested in other eye cancers and in bladder cancer. Bel sar is built from modified human papilloma virus proteins linked to molecules that are activated by light, and it has not yet been approved for sale. The company is based in Boston, Massachusetts, and its intended patients are adults with these cancers.